Zelda Therapeutics Limited, a bio-pharmaceutical company, focuses on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia.
The last earnings update was 91 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Zelda Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Zelda Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zelda Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Zelda Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Zelda Therapeutics's earnings growth to the Australia market average as no estimate data is available.
Unable to compare Zelda Therapeutics's revenue growth to the Australia market average as no estimate data is available.
Unable to determine if Zelda Therapeutics is high growth as no earnings estimate data is available.
Unable to determine if Zelda Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Zelda Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Zelda Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Zelda Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Zelda Therapeutics has no long term commitments.
This treemap shows a more detailed breakdown of
Zelda Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Zelda Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Richard Miles Hopkins, Bsc (Hons), Ph.D. is Managing Director and Director at Zelda Therapeutics Ltd since July 16, 2018. Mr. Hopkins served as the Chief Executive Officer of PharmAust Limited since March 07, 2017 until May 25, 2018. Dr. Hopkins served as the Chief Executive Officer of Phylogica Limited from July 19, 2013 to October 2016 and served as its Chief Operating Officer until July 19, 2013. He served as the Chief Scientific Officer of Phylogica Limited. He was a co-founder of Phylogica and Vice President of Research. He is an experienced pharmaceutical executive with over 10 years in corporate leadership roles. His most recent research is focussed on engineering peptide leads for drug development. He has published over 20 peer reviewed papers and is a co-inventor on over 10 patent applications, several of which have been issued in the US and Europe. He carried out postdoctoral research in yeast genetics at the Telethon Institute for Child Health Research, Perth, Western Australia and the Department of Medicine at the University of Western Australia and Murdoch University. His research focused on the development of a novel class of peptides, trademarked by Phylogica as Phylomers® and the methods to integrate them into various high throughput screening platforms such as yeast- two-hybrid and phage display. Dr. Hopkins was elected to the position of Chair of Ausbiotech (WA Branch) in 2016. Dr. Hopkins served as an Executive Director of Phylogica Limited from July 19, 2013 to July 18, 2016. He has a BSc (Hons) and completed a PhD in Molecular Parasitiology.
Insufficient data for Richard to compare compensation growth.
Insufficient data for Richard to establish whether their remuneration is reasonable compared to companies of similar size in Australia.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Zelda Therapeutics management team is about average.
Co-Founder & Non-Executive Director
Co-Founder & Non-Executive Director
Co-Founder & Executive Director
MD & Director
Clinical Trial Consultant
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Zelda Therapeutics board of directors is less than 3 years, this suggests a new board.
How Zelda Therapeutics Limited (ASX:ZLD) Can Impact Your Portfolio Volatility
Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.
Do Insiders Own Lots Of Shares In Zelda Therapeutics Limited (ASX:ZLD)?
A look at the shareholders of Zelda Therapeutics Limited (ASX:ZLD) can tell us which group is most powerful. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Zelda Therapeutics is not a large company by global standards.
Are Zelda Therapeutics Limited's (ASX:ZLD) Interest Costs Too High?
The direct benefit for Zelda Therapeutics Limited (ASX:ZLD), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is financial flexibility worth the lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding
What Type Of Shareholder Owns Zelda Therapeutics Limited's (ASX:ZLD)?
The big shareholder groups in Zelda Therapeutics Limited (ASX:ZLD) have power over the company. … With a market capitalization of AU$45m, Zelda Therapeutics is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Zelda Therapeutics
Why Zelda Therapeutics Limited's (ASX:ZLD) Ownership Structure Is Important
I am going to take a deep dive into Zelda Therapeutics Limited’s (ASX:ZLD) most recent ownership structure, not a frequent subject of discussion among individual investors. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … Therefore, it is beneficial for us to examine ZLD's ownership structure in more detail.
Are Earnings Prospects Improving For Loss-Making Zelda Therapeutics Limited's (ASX:ZLD)?
Today I will take a look at Zelda Therapeutics Limited's (ASX:ZLD) most recent earnings update (31 December 2017) and compare these latest figures against its performance over the past few years, as well as how the rest of the biotechs industry performed. … View our latest analysis for Zelda Therapeutics Did ZLD's recent earnings growth beat the long-term trend and the industry? … For Zelda Therapeutics, its most recent earnings (trailing twelve month) is -AU$1.61M, which, against the prior year's figure, has become less negative.
Should You Be Concerned About Zelda Therapeutics Limited's (ASX:ZLD) Investors?
I am going to take a deep dive into Zelda Therapeutics Limited’s (ASX:ZLD) most recent ownership structure, not a frequent subject of discussion among individual investors. … Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … Thus, investors should dig deeper into ZLD's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: With a low level of institutional ownership, investors in ZLD need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.
Zelda Therapeutics Limited (ASX:ZLD): Is Healthcare Attractive Relative To ASX Peers?
Today, I will analyse the industry outlook, and also determine whether Zelda Therapeutics is a laggard or leader relative to its healthcare sector peers. … As the company trails the rest of the industry in terms of growth, Zelda Therapeutics may also be a cheaper stock relative to its peers. … Next Steps: Zelda Therapeutics has been a biotech industry laggard in the past year.
While these are more of a long-term investor’s concern, short-term investors may find the impact of institutional trading overwhelming enough to lose out on what could be a potential opportunity. … View our latest analysis for Zelda Therapeutics ASX:ZLD Ownership Summary Nov 11th 17 Institutional Ownership Institutional investors transact in large blocks which can influence the momentum of stock prices, at least in the short-term, especially when there is a low level of public shares available on the market to trade. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions.
Is Zelda Therapeutics Limited (ASX:ZLD) Still A Cheap Healthcare Stock?
ASX:ZLD PE PEG Gauge Oct 20th 17 The biotech industry is trading at a PE ratio of 31x, above the broader Australian stock market PE of 16x. … If your initial investment thesis is around the growth prospects of ZLD, there are other biotech companies that have delivered higher growth, and perhaps trading at a discount to the industry average. … Although its growth has delivered lower growth relative to its biotech peers in the near term, the market may be pessimistic on the stock, leading to a potential undervaluation.
Zelda Therapeutics Limited, a bio-pharmaceutical company, focuses on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoids to treat diabetes-associated cognitive decline. Zelda Therapeutics Limited has strategic partnership with CannPal Pty Ltd.; and St Vincent's Hospital on opioid reduction study. The company is based in Perth, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.